Polymorph screening is an important stage of drug development. The aim is to identify the different crystalline structures or polymorphs that a drug may appropriate…
Background: Why there is a need for the Exalt™ application
Polymorph screening is an important stage of drug development. The aim is to identify the different crystalline structures or polymorphs that a drug may appropriate. The information gained is used to optimise the physical properties of the drug compound to ensure efficacy, and provide formulation and manufacturing consistency.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Once a drug compound is discovered, consideration must be given on how it will be administered to a patient. A drug compound may have poor water solubility, poor stability or a lack of crystalline form. This is usually overcome by creating a ‘salt’ version of the drug compound.
Compounds that are crystalline in nature, often adopt a number of crystalline forms or polymorphs. Different polymorphs will have different physical characteristics which can impact on the manufacturing process, which can affect the efficacy of the drug.
In the case of the anti-viral drug Ritonavir, not only was one polymorph virtually inactive compared to the alternative crystal form, but it was subsequently found to convert the active polymorph into the inactive form on contact due to its lower energy and greater stability, making spontaneous interconversion energetically favourable. Even a speck of the lower energy polymorph could convert large quantities of Ritonavir into the inactive polymorph, and this caused major production issues until the drug was finally reformulated.
It is also essential for all crystal forms to be listed on any drug patent. In the case of Prozac, an Eli Lilly drug, a generic drug manufacturer discovered another form not listed on the patent, and subsequently released a copy of the drug. A year prior to patent expiry, Eli Lilly lost several billion dollars in revenue as a result.
Regulatory authorities expect drug manufacturers to conduct thorough assessments of new drugs to form polymorphs. Pharmaceutical companies address the issues by carrying out a screen on the chosen compound to identify as many different polymorphic forms as possible. Ideally, this screen takes place at an early stage in the drug development cycle so that a manufacturing process can be defined to produce the correct form for clinical trials and the pharmaceutical market. A rational and extensive initial screen will be repeated as necessary throughout the project, for example, if the impurity profile of the material changes, the robustness of the crystallisation process will also be thoroughly investigated.
The screening process is time and resource consuming with no guarantee that all polymorphs will be discovered. It can also require a significant amount of active pharmaceutical ingredient (API). Polymorph studies are carried out manually, and each chemist usually employs slightly different approaches which can result in a lack of consistency.
Screening for polymorphs involves applying a wide range of crystallisation conditions in a number of solvents with diverse properties, (eg; polar, non-polar, aromatic etc). Applying different conditions to the materials in the solid phase may also generate new forms. Of particular importance is the variation of the rate of crystallisation – slower crystallisation typically yields thermodynamically stable forms, whereas faster experiments will produce metastable forms that may be kinetically preferred. When new forms are identified, they may, in turn, be used as input material for further experiments.
Studies for polymorph screening can therefore take a long time and may be difficult to conduct. Working with researchers in the field, Genevac Ltd has developed Exalt™, a unique toolkit to help researchers conduct evaporative crystallisation studies in a number of ways, whether polymorph screening, or searching for metastable and stable forms. Many crystallisation tools are currently available, and researchers usually use all of them in an effort to reduce the risk of new forms appearing later in the project. Although these techniques cannot all be replaced by Exalt™, most, if not all of the evaporative methods can be, so the crystalline forms of a drug can now be delivered in a controlled and reproducible manner.
The Exalt™ toolkit for use in Genevac series 2, and the latest series 3 HT systems.
The development of Exalt™ by Genevac Ltd, began with a customer request to utilise evaporation in a controlled way to produce stable crystal forms, ie; very long evaporation times, (>72 hrs), evaporation of a wide range of solvents at the same time and at the same slow rate of evaporation for every solvent, volatile through to non-volatile. Analysis by X-ray diffraction (XRD) and Thermogravimetric differential thermal analysis, (TG-DTA) confirmed the presence of true polymorphism rather than solvation.
How does it work?
The Exalt™ software allows the pressure reduction from atmospheric and the cycle time to be carefully controlled so that evaporation can take place from 6 hrs to 72 hours or more. The condenser must be able to defrost automatically every 6 hours, or a large plug of ice forms in the condenser inlet.
The combination of pressure cycling and baffles delivers slow, controlled evaporation of different solvents at the same time and at similar rates. Studies of solvents with BP’s in the range 40⁰C to 165⁰C, DCM to DMAc (including water) have been made possible.
Left to Right: Exalt baffles & tower assembly – Loading vials & towers – Complete holder assembly
Pressure cycling creates a serial dilution of the atmosphere surrounding the samples. Spinning the rotor induces a vortex in the tower, promoting vapour diffusion. This “chimney” effect helps the non-volatile solvents. Baffles slow the flow of vapour from one chamber to the next.
Towers containing baffles sit on top of the vials. The baffles have varying diameter holes, and are selected depending on the solvent properties. More baffles, with smaller holes for volatile solvents, fewer, (or no) baffles and larger holes for non-volatiles.
The tower containing the baffles has four sections; base, which can have a seal and a baffle fitted, and the remaining three top sections which can each have a baffle fitted.
The Exalt™ application will happily run on the new Genevac series 3 HT systems, or older, series 2 HT systems fitted with auto-defrost and drain condensers, ICOPS controls and version 3.06 software or later, to give an additional pressure control option, “crystallise”. This then enables the user to set the pressure reduction (from atmospheric) and the cycle time. The necessary upgrades are available on older series 2 HT systems, (depending on the age of the system, suitability can be checked by providing the manufacturer’s serial number).
Ibuprofen crystallised from Acetone (L), and Ethyl Acetate, (R)
During the summer of 2013, Researchers at Novartis Pharmaceuticals in Horsham, UK carried out a lengthy evaluation of eXalt™ technology to investigate how it may be applied to small molecule crystallisation processes in pharmaceutical chemistry R & D. A presentation with an account of this work is available below:- eXaltTechnology_NovartisPresentation 2013
Conclusions from this study were that Exalt offers a simple, reproducible method for evaporative crystallisation screening. The method is easy to use and allows late stage medicinal chemists to easily screen for crystalline forms with as little as 5mg of compound. Being non-destructive valuable compound is not lost and can be reused and knowledge gained can be used to develop a classic scalable crystallisation process. Crystals produced by exalt are high quality and suitable for XRPD analysis as well as for use as seed crystals.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.